Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

First International Summit on Interventional Pharmacoeconomics

Peter Clark, MA, MD, FRCP: A Payer Perspective

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Subgroup Analysis Demonstrates Efficacy of Inavolisib Regimen in Asian Patients With Advanced Breast Cancer

GLP-1 Receptor Agonists Linked to Lower Colorectal Cancer Risk in Patients With IBD

Chinese Study of HER2-Targeted Combination Therapy for Locally Advanced Breast Cancer

Multi-Cancer Early Detection Test Performs Well in Real-World Asian Cohort

Early Palliative Care Improves Quality of Life for Patients With Breast Cancer in India